The Latest Breaking News from Biogen

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.

Patience is a virtue but knowing the right time to apply it helps make you money.

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.